Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2018

Open Access 01-12-2018 | Correction

Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma

Authors: Du-Chu Chen, You-De Liang, Liang Peng, Yi-Ze Wang, Chun-Zhi Ai, Xin-Xing Zhu, Ya-Wei Yan, Yasmeen Saeed, Bin Yu, Jingying Huang, Yuxin Gao, Jiaqi Liu, Yi-Zhou Jiang, Min Liu, Demeng Chen

Published in: Cancer Cell International | Issue 1/2018

Login to get access

Excerpt

Upon publication of the original article [1] it was highlighted by the authors that a grant awarded to support the research work of the study was missed in the Funding Acknowledgements of their manuscript. It should also be acknowledged that the grant titled “Shenzhen healthcare research project” (201505025 to Youde Liang) also contributed to the resources for this research. This has since been formally noted in this correction article. …
Literature
1.
Metadata
Title
Correction to: CBFA2T2 is associated with a cancer stem cell state in renal cell carcinoma
Authors
Du-Chu Chen
You-De Liang
Liang Peng
Yi-Ze Wang
Chun-Zhi Ai
Xin-Xing Zhu
Ya-Wei Yan
Yasmeen Saeed
Bin Yu
Jingying Huang
Yuxin Gao
Jiaqi Liu
Yi-Zhou Jiang
Min Liu
Demeng Chen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-018-0564-5

Other articles of this Issue 1/2018

Cancer Cell International 1/2018 Go to the issue

Primary Research

Downregulation of microRNA-21 inhibited radiation-resistance of esophageal squamous cell carcinoma

Primary Research

Unique CD44 intronic SNP is associated with tumor grade in breast cancer: a case control study and in silico analysis

Primary research

M3 muscarinic acetylcholine receptors regulate epithelial–mesenchymal transition, perineural invasion, and migration/metastasis in cholangiocarcinoma through the AKT pathway

Primary Research

Integrated TCGA analysis implicates lncRNA CTB-193M12.5 as a prognostic factor in lung adenocarcinoma

Primary research

MicroRNA-770 affects proliferation and cell cycle transition by directly targeting CDK8 in glioma

Primary research

SIRT1 rs3758391 polymorphism and risk of diffuse large B cell lymphoma in a Chinese population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits